<DOC>
	<DOCNO>NCT02405260</DOCNO>
	<brief_summary>This trial multi-center , adaptive , randomize , double-blind , placebo- active- control , parallel group , Phase 2 study subject T2DM evaluate effect TTP399 HbA1c follow administration 6 month .</brief_summary>
	<brief_title>Add Glucokinase Activator Target A1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>A historical diagnosis Type 2 Diabetes accordance American Diabetes Association ( ADA ) guideline , diagnosis least 6 month prior Screening . On stable ( last 3 month prior screen ) regimen metformin monotherapy equivalent least 1000 mg daily . Males , female childbearing potential ( must negative pregnancy test willing comply protocol contraception ) , females nonchildbearing potential . Age 18 75 year , inclusive , time screen . HbA1c ≥7.0 % ≤9.5 % . Generally stable health without active infection history major surgery significant injury within last year . Diagnosis Type 1 diabetes mellitus , maturityonset diabetes young , insulinrequiring Type 2 Diabetes , unusual rare form diabetes mellitus , history diabetic ketoacidosis . Clinically significant abnormal lab value include eGFR &lt; 50ml/min/1.73m2 , ALT , bilirubin AST &gt; 1.5 X ULN , hypokalemia clinically significant electrolyte abnormality . History myocardial infarction , unstable angina , coronary revascularization , stroke , transient ischemic attack within 2 year screen . Presence symptomatic congestive heart failure . History cardiac arrhythmia require treatment prophylaxis drug device last 2 year history atrial fibrillation flutter beyond single shortterm episode ( e.g. , last 12 day ) . History presence 2nd degree great atrioventricular block absence pacemaker . A 12lead ECG , screen baseline demonstrate QTcF interval &gt; 450 msec male &gt; 47 msec female . A family personal history long QT syndrome . History pancreatitis . Persistent , uncontrolled hypertension . Presence chronic active hepatitis ( hepatitis B , hepatitis C , nonalcoholic steatohepatitis [ NASH ] ) and/or know liver cirrhosis . Participation formal weight loss program , fluctuation &gt; 5 % body weight , receive medication approve weight loss within 3 month prior screen . A positive prestudy drug screen . Participation clinical trial receipt investigational product within 30 day . Have history drug abuse within 2 year screen positive prescreen drug screen . Have history hypoglycemic episode require glucose , glucagon , orange juice administer someone patient within 6 month prior screen . A history excessive alcohol consumption within last 2 year prior screen Mental legal incapacitation . Blood donation approximately 1 pint ( 500 mL ) within 8 week . History MEN2 family history medullary thyroid cancer . History cancer , nonmelanoma skin cancer , require therapy 5 year prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>